公司消息– SyneuRx | 美容美髮公開資訊

心悅生醫與基隆長庚醫院簽署兩項精神分裂症之臨床執行合約.2021-06-23.心悅生醫現金增資募集完成，台杉生...SNB01研發進度說明.2020-07-26.SND13期中分析報告 ...

November 19, 2021 – Los Angeles, CA – SyneuRx™ International, (www.syneurx.com), a pioneering developer of novel CNS (Central Nervous System) and anti-viral pharmaceuticals, today announced that its investigational oral SARS-CoV-2 (COVID-19) anti-viral drug candidate Pentarlandir® has successfully been in Phase II US-FDA trial for several months and is nearing Phase III in 2022.

Designed as an early-stage COVID-19 treatment, Pentarlandir® is given by mouth to patients suffering either from ‘breakthrough’ cases of COVID-19 (for those who have been previously vaccinated or infected) or potentially as a first-line treatment pathway for the unvaccinated who might otherwise face potential hospitalization and death. SyneuRx has previously received ‘Breakthrough Therapy Designation and Orphan Drug Designation’ grants by the FDA for its CNS drug candidates.

Pentarlandir® is based on highly-purified...